林业发展局顶尖癌症药物官员Richard Pazdur计划在2025年底前退休, Richard Pazdur, FDA’s top cancer drug official, plans to retire by year-end 2025, amid leadership changes at the agency.

根据多个消息来源,FDA瘤卓越中心负责人理查德·帕兹杜尔宣布计划在2025年12月底退休. Richard Pazdur, head of the FDA’s Oncology Center of Excellence, has announced plans to retire at the end of December 2025, according to multiple sources. 他在会议期间通知了高级官员,尽管他的辞职不是最终的,他仍然可以撤回辞职。 He informed senior officials during a meeting, though his resignation is not final and he could still withdraw it. 林业发展局专员马蒂·马卡里任命的Pazdur在加速批准癌症药物和实现监管途径现代化方面发挥了关键作用。 Pazdur, appointed by FDA Commissioner Marty Makary, played a key role in accelerating cancer drug approvals and modernizing regulatory pathways. 他的离任加剧了林业发展局领导层的不稳定,在卫生部长罗伯特·肯尼迪(Robert F. Kennedy Jr)的领导下,林业发展局发生了一些高层变化。 His departure adds to leadership instability at the FDA, which has seen several high-level changes under Health Secretary Robert F. Kennedy Jr. 该机构尚未确认辞职,也没有指定继任者。 The agency has not yet confirmed the resignation, and no successor has been named.